|Poll|May 13, 2014

Fecal Occult Blood Test, Positive: What Study Next?

Results of upper and lower endoscopy are inconclusive. Your next step?

A 32-year-old woman presents with symptomatic anemia. A fecal occult blood test taken in the emergency room is positive. She undergoes an esophagogastroduodenoscopy (EGD) and colonoscopy, both of which are unrevealing.

Which of the following studies should be performed next?

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Fecal Occult Blood Test, Positive: What Study Next?

Related Content

ASPIRE-CD Highlights Patient-Reported Symptom Gains With Risankizumab in Crohn Disease

Mental Health Screening May Improve Psychogastroenterology Follow-Up in IBD Care: A Q&A

Mirikizumab Maintains UC Disease Clearance Over 4 Years in LUCENT-3, With Jean-Frédéric Colombel, MD

Risankizumab, Upadacitinib Show Durable Real-World IBD Outcomes at DDW 2026

Mirikizumab Sustains UC Disease Clearance at Four Years in LUCENT-3 Extension Data

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, Maintenance, and Beyond! – Arizona

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Iowa Oncology Society

Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

Wyoming State Oncology Society

Tennessee Oncology Practice Society

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Kansas Society of Clinical Oncology

North Carolina Oncology Association

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Breaking the Demodex Blepharitis Cycle: The Importance of Early Intervention

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Southern California Psychiatry Conference

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

10th Annual Live Medical Crossfire®: Hematologic Malignancies

25th Annual International Congress on the Future of Breast Cancer® East

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Retina Updates in Montréal

25th Annual International Congress on the Future of Breast Cancer® West

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Kentucky Society of Clinical Oncology

Rhode Island Oncology Society

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

27th Annual International Lung Cancer Congress®

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)